Physician profile
Daniel Rosa
NPI 1568592962
$4,251.89
in general payments reported to CMS, 2019-2025
23 companies · $1,277 in 2025
The $1,277 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,871 · 2020: $170 · 2021: $57.47 · 2022: $21.25 · 2023: $189 · 2024: $666 · 2025: $1,277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,132.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $892.23 | 2019-2025 | Cabenuva, Apretude |
| Abbvie INC. | $490.85 | 2019-2025 | |
| Gilead Sciences, INC. | $420.12 | 2019-2025 | Yeztugo, Epclusa |
| Alkermes, INC. | $357.51 | 2024-2025 | Aristada, Lybalvi, Vivitrol |
| Smith+Nephew, INC. | $354.05 | 2019 | |
| Sunovion Pharmaceuticals INC. | $283.56 | 2019 | |
| Janssen Products, Lp | $274.16 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $207.43 | 2019 | |
| Emd Serono, INC. | $191.32 | 2019-2025 | Serostim |
| Exact Sciences Corporation | $186.92 | 2023-2025 | Cologuard Collection Kit |
| Janssen Biotech, INC. | $105.25 | 2019-2020 | |
| Indivior INC. | $88.05 | 2019-2024 | Sublocade |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $81.83 | 2024-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $81.60 | 2019-2021 | |
| Pfizer INC. | $60.74 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $32.85 | 2019 | |
| Axsome Therapeutics, INC. | $30.55 | 2025 | Auvelity |
| Melinta Therapeutics, LLC | $23.62 | 2019 | |
| Hologic Sales and Service, LLC | $23.35 | 2025 | Aptima |
| Avanir Pharmaceuticals, INC. | $22.43 | 2019 | |
| Orexo US, INC. | $16.53 | 2019 | |
| Lundbeck LLC | $15.95 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Rosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.